NewTimeSpace News: JIUYUAN GENE(02566.HK) released a voluntary announcement on February 9, 2026, disclosing the latest progress in its innovative drug research and development, with the core being the acceptance of the IND application for JY54 Injection.

The announcement stated that JY54 Injection is a self-developed Class 1 chemical innovative drug of the company and a long-acting amylin analog. By simulating the mechanism of action of natural amylin and binding to amylin receptors, it exerts multiple biological effects to facilitate blood glucose control and weight management. Preclinical trial data have shown outstanding performance in all indicators of the drug, and it has significant synergistic potential when used in combination with marketed anti-obesity drugs.

It is reported that JIUYUAN GENE plans to launch Phase I clinical trials for JY54 Injection, focusing on evaluating the drug's safety, tolerability, pharmacokinetics and pharmacodynamics in subjects. The acceptance of this IND application marks the official entry of the drug into the clinical trial stage, which will further enrich the company's innovative drug pipeline and enhance its core competitiveness.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.